RHHBY - Monte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analyst | Benzinga
Wedbush initiated coverage on Monte Rosa Therapeutics Inc (NASDAQ:GLUE), a company focused on developing molecular glue degraders (MGDs) against several inadequately drugged cancer and autoimmune disease targets.
The analyst notes that the company’s lead programs are highly differentiated, with development supported by strong biological and genetic rationale, and sees significant potential for value creation as they progress.
Monte Rosa Therapeutics’ proprietary AI/ML-based QuEEN platform is designed to identify proteins amenable to target by degradation, allowing the generation of a rational, proprietary library of compounds that may further accelerate discovery.
Wedbush has initiated Monte Rosa Therapeutics with an Outperform rating and a price target of $11.
Monte Rosa Therapeutics’ lead asset, MRT -2359, ...